http://www.bloomberg.com/apps/news?pid= ... HAvoYYYAIE
On his watch, Biogen temporarily recalled one of its top-sellers, the multiple sclerosis drug Tysabri, after it was linked to deadly brain infections. Since the therapy returned to the market in 2006, Mullen hasn’t reached his goal to have 100,000 patients use it; Tysabri is used by about 48,800 patients, said company spokeswoman Amy Reilly.
Biogen shares Tysabri’s revenue with marketing partner Elan Corp. of Dublin.
Andreas from Germany
I did missunderstand the text.